Thilo Schroeder Sells 13,272 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Director Thilo Schroeder sold 13,272 shares of the stock in a transaction on Monday, September 13th. The stock was sold at an average price of $30.20, for a total transaction of $400,814.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Thilo Schroeder also recently made the following trade(s):

  • On Thursday, September 9th, Thilo Schroeder sold 14,329 shares of PMV Pharmaceuticals stock. The stock was sold at an average price of $30.31, for a total transaction of $434,311.99.
  • On Wednesday, September 1st, Thilo Schroeder sold 21,986 shares of PMV Pharmaceuticals stock. The stock was sold at an average price of $30.38, for a total transaction of $667,934.68.
  • On Monday, August 30th, Thilo Schroeder sold 13,233 shares of PMV Pharmaceuticals stock. The stock was sold at an average price of $30.05, for a total transaction of $397,651.65.
  • On Friday, August 27th, Thilo Schroeder sold 24,442 shares of PMV Pharmaceuticals stock. The stock was sold at an average price of $30.52, for a total transaction of $745,969.84.
  • On Wednesday, August 25th, Thilo Schroeder sold 13,526 shares of PMV Pharmaceuticals stock. The shares were sold at an average price of $31.01, for a total transaction of $419,441.26.
  • On Wednesday, August 18th, Thilo Schroeder sold 26,864 shares of PMV Pharmaceuticals stock. The shares were sold at an average price of $33.34, for a total transaction of $895,645.76.
  • On Monday, August 16th, Thilo Schroeder sold 22,183 shares of PMV Pharmaceuticals stock. The shares were sold at an average price of $33.89, for a total transaction of $751,781.87.
  • On Friday, August 13th, Thilo Schroeder sold 27,286 shares of PMV Pharmaceuticals stock. The shares were sold at an average price of $34.24, for a total transaction of $934,272.64.
  • On Wednesday, August 11th, Thilo Schroeder sold 34,439 shares of PMV Pharmaceuticals stock. The shares were sold at an average price of $34.04, for a total transaction of $1,172,303.56.
  • On Monday, August 9th, Thilo Schroeder sold 22,182 shares of PMV Pharmaceuticals stock. The shares were sold at an average price of $35.53, for a total transaction of $788,126.46.

PMVP stock opened at $28.46 on Wednesday. PMV Pharmaceuticals, Inc. has a 12 month low of $25.01 and a 12 month high of $63.22. The firm has a market cap of $1.29 billion and a P/E ratio of 18.72. The company’s 50-day moving average price is $32.49 and its two-hundred day moving average price is $33.62.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its earnings results on Thursday, August 12th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.01). As a group, equities research analysts forecast that PMV Pharmaceuticals, Inc. will post -1.18 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of PMVP. OLD Mission Capital LLC acquired a new stake in shares of PMV Pharmaceuticals in the 3rd quarter valued at approximately $1,835,000. Victory Capital Management Inc. boosted its stake in shares of PMV Pharmaceuticals by 21.9% in the 1st quarter. Victory Capital Management Inc. now owns 799,001 shares of the company’s stock valued at $26,279,000 after purchasing an additional 143,292 shares in the last quarter. Hamilton Lane Advisors LLC acquired a new stake in shares of PMV Pharmaceuticals in the 1st quarter valued at approximately $202,000. Alliancebernstein L.P. boosted its stake in shares of PMV Pharmaceuticals by 5.4% in the 1st quarter. Alliancebernstein L.P. now owns 9,800 shares of the company’s stock valued at $322,000 after purchasing an additional 500 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of PMV Pharmaceuticals by 6.0% in the 1st quarter. BlackRock Inc. now owns 1,425,873 shares of the company’s stock valued at $46,897,000 after purchasing an additional 80,858 shares in the last quarter. Institutional investors own 93.30% of the company’s stock.

Several equities analysts have recently weighed in on the stock. Guggenheim assumed coverage on shares of PMV Pharmaceuticals in a research report on Monday, August 2nd. They issued a “buy” rating and a $56.00 price objective on the stock. Oppenheimer assumed coverage on shares of PMV Pharmaceuticals in a research report on Thursday, August 19th. They set a “market perform” rating on the stock. Zacks Investment Research lowered shares of PMV Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, September 10th. Finally, HC Wainwright assumed coverage on shares of PMV Pharmaceuticals in a research report on Thursday, July 29th. They set a “buy” rating and a $63.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $45.40.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function.

Featured Story: What is the definition of a trade war?

Insider Buying and Selling by Quarter for PMV Pharmaceuticals (NASDAQ:PMVP)

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.